KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Total Non-Current Liabilities rose 951.09% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 951.09%. This contributed to the annual value of $3.8 billion for FY2024, which is 100.67% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Total Non-Current Liabilities of $4.2 billion as of Q3 2025, which was up 951.09% from $3.9 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities registered a high of $4.2 billion during Q3 2025, and its lowest value of $2.3 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $3.6 billion (2023), whereas its average is $3.4 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 14640.22% in 2021 and then tumbled by 128.17% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Total Non-Current Liabilities stood at $3.0 billion in 2021, then grew by 18.13% to $3.5 billion in 2022, then grew by 7.16% to $3.7 billion in 2023, then grew by 1.01% to $3.8 billion in 2024, then increased by 10.54% to $4.2 billion in 2025.
  • Its Total Non-Current Liabilities was $4.2 billion in Q3 2025, compared to $3.9 billion in Q2 2025 and $3.7 billion in Q1 2025.